Cochrane · systematic review · CD003044
Non‐absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis
Gluud, LL, Vilstrup, H, Morgan, MY · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
10
current version
GRADE rated
9
No studies
1
Included studies
NR
No studies 1 · 10%Ungraded 0 · 0%Very low 6 · 60%Low 0 · 0%Moderate 3 · 30%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 2 versionsNon‐absorbable disaccharides versus placebo/no intervention for the prevention and treatment of hepatic encephalopathy in people with cirrhosis
Population: prevention and treatment of hepatic encephalopathy in people with cirrhosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality Non‐absorbable disaccharides vs placebo/no intervention | RR 0.59 [0.4, 0.87] | 24 studies · 1487 participants | Moderate |
Hepatic encephalopathy Non‐absorbable disaccharides vs placebo/no intervention | RR 0.58 [0.5, 0.69] | 22 studies · 1415 participants | Moderate |
Serious adverse events Non‐absorbable disaccharides vs placebo/no intervention | RR 0.47 [0.36, 0.6] | 24 studies · 1487 participants | Moderate Downgraded: inconsistency |
Quality of life (secondary outcome) Non‐absorbable disaccharides vs placebo/no intervention | no estimate extracted | NR | Very low Downgraded: inconsistency |
Non‐serious adverse events (secondary outcome) Non‐absorbable disaccharides vs placebo/no intervention | RR 2.47 [1.24, 4.93] | 9 studies · 739 participants | Very low Downgraded: inconsistency |
Lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis
Population: prevention and treatment of hepatic encephalopathy in people with cirrhosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality Lactulose vs lactitol | RR 1.3 [0.59, 2.85] | 8 studies · 225 participants | Very low |
Hepatic encephalopathy Lactulose vs lactitol | RR 1 [0.84, 1.19] | 7 studies · 194 participants | Very low |
Serious adverse events Lactulose vs lactitol | RR 1.56 [0.84, 2.88] | 9 studies · 245 participants | Very low |
Quality of life (secondary outcome) Lactulose vs lactitol | no estimate extracted | NR | No studies |
Non‐serious adverse events (secondary outcome) Lactulose vs lactitol | RR 1.55 [0.88, 2.74] | 6 studies · 169 participants | Very low |